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Abstract
Objectives. To predict the occurrence of inactive disease in JIA in the first 2 years of disease.
Methods. An inception cohort of 152 treatment-naı¨ve JIA patients with disease duration <6 months was analysed.
Potential predictors were baseline clinical variables, joint US, gut microbiota composition and a panel of inflammation-
related compounds in blood plasma. Various algorithms were employed to predict inactive disease according to Wallace
criteria at 6-month intervals in the first 2 years. Performance of the models was evaluated using the split-cohort tech-
nique. The cohort was analysed in its entirety, and separate models were developed for oligoarticular patients, poly-
articular RF negative patients and ANA positive patients.
Results. All models analysing the cohort as a whole showed poor performance in test data [area under the curve (AUC):
<0.65]. The subgroup models performed better. Inactive disease was predicted by lower baseline juvenile arthritis DAS
(JADAS)-71 and lower relative abundance of the operational taxonomic unit Mogibacteriaceae for oligoarticular patients
(AUC in test data: 0.69); shorter duration of morning stiffness, higher haemoglobin and lower CXCL-9 levels at baseline
for polyarticular RF negative patients (AUC in test data: 0.69); and shorter duration of morning stiffness and higher
baseline haemoglobin for ANA positive patients (AUC in test data: 0.72).
Conclusion. Inactive disease could not be predicted with satisfactory accuracy in the whole cohort, likely due to
disease heterogeneity. Interesting predictors were found in more homogeneous subgroups. These need to be validated
in future studies.
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Rheumatology key messages
. Inactive disease could not be predicted with satisfactory accuracy in JIA patients.
. Interesting predictors were found in JIA disease subgroups that need validation in future studies.
. Better characterization of homogeneous subgroups could improve the understanding of the prognosis of JIA.
Introduction
JIA is an umbrella term covering chronic arthritis of un-
known cause lasting for >6 weeks with an onset before
16 years of age [1]. The prognosis of children with JIA has
improved considerably over the past decades. Following
the advent of MTX and biologic agents, many children
achieve disease remission within a reasonable time
frame [25]. Nevertheless, there is still a substantial pro-
portion of children who do not achieve inactive disease, or
fail to do so within a short period of time. Prolonged dis-
ease activity causes distress, diminishes the overall well-
being of the child and is associated with a higher risk of
long term sequelae of the disease, including irreversible
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joint damage [610]. On top of this, in adult RA, better
outcomes are achieved if effective treatment is started
early in the course of disease, the so-called window of
opportunity [1115]. Even though JIA differs substantially
from adult RA in terms of clinical presentation and prog-
nosis, such a window of opportunity might also be present
in paediatric rheumatology.
For various reasons, it is not feasible to prescribe bio-
logic agents to all children with JIA. First, this would
expose many children to the potential side effects of the
drugs and, secondly, this practice would be too costly.
Moreover, not all children need biologic agents, since
some respond well to intra-articular corticosteroid injec-
tions only, or failing that strategy, may benefit from the
addition of MTX [16].
Therefore, since all children should receive early and
effective treatment and not all children should be pre-
scribed biologic agents, there is a clinical need of pre-
dictors capable of stratifying JIA patients according to
their prognosis, thus enabling identification early in the
course of disease, ideally at the time of diagnosis, of
those patients in need of more aggressive therapy.
A review of the literature revealed that it is unlikely that
clinical predictors suffice to achieve that goal [17]. This
conclusion was challenged by a recently published clinical
prediction model that performed well in test data [18].
However, its performance was poor in our cohort.
Therefore, other categories of predictors need to be
taken into consideration for the accurate prediction of
the prognosis of JIA.
Our aim was to construct a prediction model of the
prognosis of JIA patients in a well-defined, multicentre
cohort, using clinical, imaging and microbiota data as
well as a panel of inflammation-related compounds in
blood plasma.
Methods
We performed a prospective, observational cohort study
at the Istituto Giannina Gaslini (IGG, Genoa, Italy),
Ospedale Pediatrico Bambino Gesu` (OPBG, Rome, Italy)
and the Wilhelmina Children’s Hospital (WKZ, Utrecht, The
Netherlands), between October 2013 and December 2015
(IGG and OPBG) and between March 2014 and December
2015 (WKZ). The study was approved by the local medical
ethics committees of the Istituto Giannina Gaslini in
Genoa, the Ospedale Pediatrico Bambino Gesu` in Rome
and the Wilhelmina Children’s Hospital in Utrecht and all
participating patients or their parents (where appropriate)
provided written informed consent prior to participation.
The study was conducted according to good clinical prac-
tice guidelines and the Declaration of Helsinki.
Consecutive patients with JIA according to International
League Against Rheumatism criteria [19] at disease onset
(onset of symptoms at most 6 months before enrolment)
who had not started any treatment other than NSAIDs
were eligible for enrolment. Systemic JIA patients were
not included.
At baseline, clinical parameters regarding demograph-
ics and disease manifestations were collected and routine
laboratory examinations were performed. The childhood
health assessment questionnaire was completed by the
child or the parents. Information about ongoing treatment
(NSAIDs) was collected. An additional sample of blood
was collected, and peripheral blood plasma was isolated
and frozen at 80C. These samples were then shipped
to WKZ on dry ice by overnight shipment to perform an in-
house developed and validated (ISO9001 certified) multi-
plex immunoassay (Laboratory of Translational
Immunology, University Medical Centre Utrecht) based
on Luminex technology (xMAP, Luminex, Austin, TX,
USA). The assay was performed as described previously
[20]. Aspecific heterophilic immunoglobulins were pre-
absorbed from all samples with heteroblock (Omega
Biologicals, Bozeman, MT, USA). Acquisition was per-
formed with the Bio-Rad FlexMAP3D (Bio-Rad labora-
tories, Hercules, CA, USA) in combination with
xPONENT software version 4.2 (Luminex). Data were ana-
lysed by five-parametric curve fitting using Bio-Plex
Manager software, version 6.1.1 (Bio-Rad).
Additionally, a stool sample for gut microbiota deter-
mination was collected and frozen at 80C. These sam-
ples were shipped to OPBG on dry ice by overnight
shipment for 16S bacterial ribosomal RNA pyrosequen-
cing, as described in literature [21]. Reads were analysed
by QIIME v.1.8.0, grouped into operational taxonomic
units (OTUs) at a sequence similarity level of 97%
[2225] (Van Dijkhuizen et al. manuscript in preparation).
Finally, an extended joint ultrasonography was per-
formed using a pre-specified protocol. Details of the
protocol have been published previously [26]. All available
covariates are listed in supplementary Table S1, available
at Rheumatology online.
Enrolled patients were evaluated every 6 months and
additionally in the case of a relapse, for 2 years or until
the end of the study period in February 2017, whichever
was first. At each visit, disease activity was assessed
using the Wallace criteria for inactive disease [27].
Ongoing treatment was categorized as: no treatment;
intra-articular joint injections with or without NSAIDs;
MTX with or without oral steroids; and biological agents.
Statistical analysis
To assess the predictive performance of the Luminex and
microbiota data over clinical data only, three different pre-
diction models were developed, one consisting of clinical
(including US) data only, one containing clinical and
microbiota data, and one using clinical and Luminex
data. All described models included treatment and the
interval of time elapsed between baseline and the fol-
low-up visits as covariates. The outcome was inactive dis-
ease versus active disease for all models. Missing clinical
data were imputed by multiple imputations using chained
equations producing 10 imputed datasets [28]. All other
clinical variables, including the outcome, were used in the
imputations, provided they were not linearly related to the
variables to be imputed [28]. Missing microbiota and
Luminex data were only due to missing samples in our
cohort and were therefore not imputed.
https://academic.oup.com/rheumatology 1753
Prediction of inactive disease in JIA
D
ow
nloaded from
 https://academ
ic.oup.com
/rheum
atology/article-abstract/57/10/1752/5042122 by Istituto G
iannina G
aslini user on 26 N
ovem
ber 2019
The cohort was split at random into two-thirds for
model training and one-third for model validation. To elim-
inate the influence of the data split on the model evalu-
ation, the split was performed 10 times and the model was
trained and tested in each of these split datasets.
The performance was summarized as the mean over the
10 splits.
In the training data, univariate variable selection was
performed by fitting a model and retaining the variables
with a P< 0.1, or P< 0.2 in cases in which no variable had
a P< 0.1. If variables correlated in training data
(Spearman’s jrj> 0.6), the variable with the lowest
P-value was retained. The remaining variables were
pooled in a multivariable model in the training data and
this model was subsequently applied to the test data.
Several different algorithms were tried and model per-
formance was assessed in an appropriate manner for
each algorithm. In the primary analysis, to exploit the in-
formation contained in all visits for all patients, a repeated
measurements analysis using generalized estimating
equations (GEE) was performed [29, 30]. Performance of
this model was tested using an area under the curve
(AUC)-like statistic, adapted to models with repeated
measurements [31].
Secondary analyses
Various secondary analyses were performed, including
Cox proportional hazards models of time to first inactive
disease and Cox regressions of time to inactive disease,
using recurrent events analysis [32]. The performance of
these models was assessed by predicting the risk score of
patients in the test data and correlating this risk score with
the observed outcome in the test dataset, using Somer’s
D correlation, adapted to censored data [33, 34], from
which the c-statistic (similar to the AUC) was calculated.
Moreover, next to the longitudinal approach, the out-
comes at 6 and 12 months after baseline were analysed
separately. This approach opened up the possibility of
applying more algorithms: we fitted logistic regression
models, random forests and support vector machines.
Performance of these models was assessed by calculat-
ing the AUC.
Finally, to reduce the heterogeneity of JIA, we fitted
models to the groups of oligoarticular patients, polyarticu-
lar RF negative patients and ANA positive patients separ-
ately. Patients were pragmatically considered ANA
positive, if they had at least one positive ANA determin-
ation at baseline (titre 51:160). Statistical analyses were
carried out using R 3.3.2 (R Foundation for Statistical
Computing, Vienna, Austria).
Results
Of 169 enrolled patients, 10 were enrolled after the start of
MTX and seven were lost to follow-up (i.e. no follow-up
data collected at all), leaving 152 patients to be analysed.
Luminex data were available for 121 patients and gut
microbiota data for 91 patients (supplementary
Table S2, available at Rheumatology online). Missing
Luminex and microbiota data were due to difficulties in
the collection or shipment of samples and were unrelated
to disease characteristics. Blood samples for Luminex
analysis were collected in EDTA tubes at OPBG (com-
pared with sodium heparin tubes at IGG and WKZ).
Consequently, the Luminex results of OPBG patients
were incomparable with those of the remainder of patients
(data not shown). Therefore, the Luminex results of OPBG
patients were excluded from the analysis. Thus, the clin-
ical models were developed in 152 patients, contributing
508 visits, the microbiota models in 91 patients contribut-
ing 310 visits and the Luminex models in 80 patients con-
tributing 261 visits.
Baseline characteristics are shown in Table 1. The ma-
jority of patients were female, presented with four active
joints or fewer and continued to have persistent oligoar-
thritis. Almost 90% of patients with oligoarticular disease
onset and all patients with polyarticular onset presented
with high disease activity, according to the cut-off points
of the juvenile arthritis disease activity score (JADAS)-71
[35]. Most patients achieved inactive disease during fol-
low-up, but a substantial minority (about 2040%) showed
active disease at the follow-up visits (Table 2).
Primary analysis
The best GEE model for all patients combined is pre-
sented in supplementary Table S3, available at
Rheumatology online, showing poor performance in test
data (AUC: 0.65).
Secondary analyses
The results of the Cox models for time to first remission,
Cox models with recurrent events, and the logistic regres-
sion at 6 and 12 months are shown in supplementary
Tables S4S7, available at Rheumatology online. All
models, as well as the random forest and support vector
machine algorithms (data not shown), performed poorly in
test data.
Improved results were obtained when fitting a GEE
model to the oligoarticular patients, polyarticular RF nega-
tive patients and ANA positive patients separately. For
oligoarticular patients, the best model was the model
with clinical and microbiota predictors. The odds of
achieving inactive disease were decreased by a higher
JADAS-71 score at baseline and higher relative abun-
dance of the OTU Mogibacteriaceae. Other variables
were associated in univariate analysis, but lost signifi-
cance in the multivariable model (Table 3). The mean
AUC over the imputed datasets was 0.79 in training data
and 0.69 in test data (compared with 0.65 for the model
with clinical variables only).
The best model for the polyarticular RF negative
patients was the model with clinical and Luminex pre-
dictors. Among the variables associated in univariate ana-
lysis, the haemoglobin level and the ESR were correlated
(Spearman’s r=0.71), and therefore the ESR was
excluded. Likewise, the chemokine CXCL-9 correlated
with soluble VEGF receptor 1 (sVEGF-R1; Spearman’s
r= 0.88), and therefore sVEGF-R1 was excluded. The
multivariable model is shown in Table 4. The odds of
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achieving inactive disease were decreased by a longer
duration of morning stiffness, lower haemoglobin levels
and higher CXCL-9 levels at baseline (supplementary
Fig. S1, available at Rheumatology online). The mean
AUC over the imputed datasets was 0.79 in training data
and 0.69 in test data (marginally higher than the model
with clinical predictors only, which had an AUC of 0.67).
CXCL-9 was subsequently dichotomized. The best cut-off
was at 30 pg/ml (supplementary Fig. S1, available at
Rheumatology online), yielding an AUC of 0.78 in training
data and 0.69 in test data. The sensitivity of this cut-off to
predict patients achieving inactive disease at maximally
50% of follow-up visits was 0.31. The specificity was 0.94.
Finally, for the ANA positive patients, the best model
was the clinical model (Table 5). The odds of achieving
inactive disease were decreased by a duration of morning
stiffness >2 h and lower haemoglobin levels at baseline.
The mean AUC over the imputed datasets was 0.79 in
training data and 0.72 in test data.
The predicted probabilities of inactive disease accord-
ing to the three models as a function of the significant
predictors are illustrated in Fig. 1.
Discussion
The aim of this study was to develop a prediction model
for the prognosis of JIA patients in the first 2 years of
disease. The strength of the study was that we collected
clinical, imaging, microbiota and Luminex data in a well-
defined cohort of treatment-naı¨ve JIA patients at onset.
The prognostic value of these variables has never been
analysed before. We employed a large number of statis-
tical algorithms, taking a longitudinal approach by incor-
porating outcome information of all visits, as well as
performing survival analysis and cross-sectional analyses
at 6 and 12 months after diagnosis and initiation of treat-
ment. Moreover, machine learning algorithms such as
random forest and support vector machines were used.
Nevertheless, we were unable to construct a prediction
model with satisfying accuracy in the prediction of inactive
disease according to Wallace criteria, in all patients
together.
Despite the failure to develop a model in all patients
together, we were able to generate prediction models
for oligoarticular, polyarticular RF negative and ANA posi-
tive patients separately, even though the performance in
test data was still only moderate (AUC: 0.690.72). For the
oligoarticular patients, the odds of attaining inactive dis-
ease decreased following a higher JADAS-71 score and
higher relative abundance of the OTU Mogibacteriaceae at
baseline (Table 3). For polyarticular RF negative patients,
the odds of inactive disease decreased following a longer
duration of morning stiffness, lower haemoglobin levels
and higher CXCL-9 levels at baseline (Table 4). Similarly,
the odds of inactive disease decreased following a dur-
ation of morning stiffness >2 h and lower haemoglobin
levels at baseline, for ANA positive patients (Table 5).
TABLE 1 Baseline characteristics
n = 152
Baseline variables
Female, n (%) 112 (73.7)
Age at onset, median (IQR) 4.0 (2.17.8)
Disease duration, median (IQR) 0.2 (0.20.3)
Age at diagnosis/enrolment, median (IQR) 4.3 (2.48.2)
Active joints, median (IQR) 2 (1, 5)
More than four active joints, n (%) 43 (28.3)
JADAS-71, median (IQR) 13.2 (8.218.6)
ANA positive, n (%)a 84 (55.3)
RF positive, n (%)a 2 (1.3)
Uveitis, n (%) 8 (5.3)
Luminex data, n (%) 121 (79.6)
Gut microbiota data, n (%) 91 (59.9)
ILAR category at 6 months’ follow-up
Oligoarthritis persistent, n (%) 90 (59.2)
Oligoarthritis extended, n (%) 5 (3.3)
Polyarthritis RF positive, n (%) 2 (1.3)
Polyarthritis RF negative, n (%) 43 (28.3)
PsA, n (%) 5 (3.3)
ERA, n (%) 4 (2.6)
Undifferentiated arthritis, n (%) 3 (2.0)
aMissing clinical variables were imputed: ANA, n= 6; JADAS-
71, n= 10; RF, n= 33. ILAR: International League Against
Rheumatism; JADAS: juvenile arthritis DAS.
TABLE 2 Observed disease activity status according to Wallace criteria in the entire cohort and the three main
subgroups
Time point
Entire cohort Oligoarticular Polyarticular RF negative ANA positive
N ID, n (%) N ID, n (%) N ID, n (%) N ID, n (%)
6 months 151 89 (58.9) 51 34 (66.7) 29 14 (48.3) 87 49 (56.3)
12 months 139 103 (74.1) 47 36 (76.6) 27 18 (66.7) 81 58 (71.6)
18 months 110 87 (79.1) 41 34 (82.9) 23 17 (73.9) 64 51 (79.7)
24 months 82 61 (74.4) 31 24 (77.4) 16 10 (62.5) 53 45 (84.9)
Additional flare visits 26 0 (0) 9 0 (0) 5 0 (0) 13 0 (0)
ID: inactive disease.
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Associations in a prediction model do not prove caus-
ality. Nonetheless, the predictors in these models merit
further attention. Regarding the model for oligoarticular
patients, intuitively it is convincing that patients with
higher disease activity at baseline experience decreased
odds of achieving inactive disease. Nothing is known
about Mogibacteriaceae in the context of autoimmune
diseases. In our previous analysis, there was no difference
in the relative abundance of Mogibacteriaceae between
JIA patients and healthy children (Van Dijkhuizen et al.,
manuscript in preparation). Mogibacteriaceae were less
abundant in obese Japanese people, with respect to
lean subjects [36], and a decreased abundance of
Mogibacteriaceae in the bronchial microbiome of asth-
matic subjects has been observed [37].
Regarding the predictors for the polyarticular RF nega-
tive and the ANA positive patients, a longer duration of
morning stiffness was associated with decreased odds
of achieving inactive disease. Notably, this predictor was
very consistent in all the algorithms that were employed
TABLE 3 Best performing GEE model oligoarticular patients (n= 52)
Parameter Visits (m= 179) OR (95% CI) Wald P-value
Intercept 2.79 (0.37, 21.10) 0.99
Duration of morning stiffness
None or <15 min 105 (58.7) Reference category
15 min to 2 h 49 (27.4) 1.28 (0.38, 4.27) 0.69
>2 h 25 (14.0) 0.26 (0.05, 1.45) 0.12
Knee involvement (count) 0.67 (0.29, 1.53) 0.34
JADAS-71 0.89 (0.80, 0.997) 0.04
Christensenella 0.85 (0.69, 1.04) 0.11
Mogibacteriaceae 0.82 (0.68, 0.98) 0.03
Therapy during follow-up
None 53 (29.6) Reference category
IACI ± NSAIDs 43 (24.0) 2.35 (0.78, 7.05) 0.13
MTX ± steroids or biologic agents 83 (46.4) 2.60 (0.81, 8.32) 0.11
Interval between baseline and visit, y 2.31 (0.89, 5.96) 0.08
AUC-like statistic
Minimum Mean Maximum
Training data 0.79 0.79 0.79
Test data 0.69 0.69 0.70
Included variables showed a univariate P<0.1 and no bivariate correlations (Spearman’s jrj4 0.6). AUC:
area under the curve; GEE: generalised estimating equations; IACI: intra-articular corticosteroid injections;
JADAS: juvenile arthritis DAS; m: number of visits; n: number of patients.
TABLE 4 Best performing GEE model polyarticular RF negative patients (n= 29)
Parameter Visits (m= 100) OR (95% CI) Wald P-value
Intercept 0.02 (0.0002, 1.54) 0.08
Duration of morning stiffness
None or <15 min 21 (21) Reference category
15 min to 2 h 54 (54) 0.26 (0.08, 0.84) 0.02
>2 h 25 (25) 0.27 (0.09, 0.85) 0.03
Haemoglobin 1.52 (1.07, 2.16) 0.02
CXCL-9 0.98 (0.97, 0.996) 0.009
Therapy during follow-up
Biologic agents 14 (14) 2.80 (0.96, 8.16) 0.06
Interval between baseline and visit, y 2.37 (0.84, 6.69) 0.10
AUC-like statistic
Minimum Mean Maximum
Training data 0.79 0.79 0.79
Test data 0.69 0.69 0.69
Included variables showed a univariate P<0.1 and no bivariate correlations (Spearman’s jrj4 0.6). AUC:
area under the curve; CXCL-9: chemokine C-X-C motif ligand 9; GEE: generalized estimating equations;
m: number of visits; n: number of patients.
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(supplementary Tables S2S6, available at Rheumatology
online). In a previous analysis, it was also a determinant of
the satisfaction of JIA patients with their current illness
condition (Del Giudice et al., manuscript in preparation).
These findings highlight the importance of the patient’s
opinion in the evaluation of disease activity and support
the notion of taking their evaluation into account in thera-
peutic decision-making. Indeed, the value of the clinical
JADAS as a criterion for treatment escalation improved
when the patient’s opinion was fully taken into account
[38]. Haemoglobin level was correlated with the ESR and
therefore was thought to be reflective of anaemia of
chronic disease, making the relationship between a low
haemoglobin level and decreased odds of achieving in-
active disease convincing.
CXCL-9 is a pro-inflammatory chemokine induced by
IFN-g and is a ligand of CXCR-3. It induces Th 1 and 17
cells and recruits these to sites of inflammation. Indeed,
CXCR-3 positive cells are highly enriched in the synovium
of inflamed joints in RA [3942] and JIA [43]. Moreover,
due to its role in osteoclast activation, it may be involved
in the development of bone erosions [44]. In JIA, synovial
expression of CXCL-10, another ligand of CXCR-3 with
function very similar to CXCL-9, was increased [45, 46].
Taken together, the potential role of this chemokine in the
pathogenesis of JIA merits further investigation. The cut-
off of 30 pg/ml may be used to identify patients with worse
prognosis, but needs validation in future studies.
A recent review of the literature showed that accurate
prediction of JIA prognosis using clinical variables alone is
unlikely to be achieved [17]. Nevertheless, a clinical pre-
diction model was published recently, showing good pre-
dictive performance in test data (AUC: 0.85) [18]. The best
AUC of this model was 0.68 in our data, obtained when
classifying patients as those who never achieved inactive
disease vs those who achieved it at least once. However,
few patients (n= 11) were in the unfavourable category
and only one of these was predicted correctly. Thus,
these results reinforced the doubts about the prognostic
value of clinical data. We are now the first to demonstrate
that gut microbiota composition and Luminex data are in-
sufficient to predict JIA prognosis as well. Nevertheless,
improved prediction accuracy may be expected when
separating JIA patients into more homogeneous sub-
groups. This finding supports previously made sugges-
tions for a revision of the JIA classification criteria
[4750], and is in line with a recently published report of
long-term follow-up of Greek JIA patients showing that
JIA is a heterogeneous disease with significant variability
in long-term outcome [51].
A limitation of our study is the number of patients and
visits with respect to the number of predictors tested.
According to some, 40 cases are needed per screened
predictor [52]. However, in our situation, this would
amount to a cohort of over 10 000 children. It is not feas-
ible to collect full clinical, immunological and gut micro-
biota data of such a large cohort of JIA patients.
Nevertheless, the prediction models developed in the
secondary analyses have to be interpreted with caution
(especially the model for polyarticular RF negative
TABLE 5 Best performing GEE model ANA positive patients (n= 88)
Parameter Visits (m= 298) OR (95% CI) Wald P-value
Intercept 0.001 (6.2  106, 0.17) 0.008
Duration of morning stiffness
None 88 (29.5) Reference category
<15 min 39 (13.1) 2.16 (0.55, 8.40) 0.27
15 min to 1 h 79 (26.5) 0.78 (0.25, 2.37) 0.66
12 h 40 (13.4) 1.52 (0.39, 5.88) 0.55
>2 h 52 (17.4) 0.26 (0.10, 0.69) 0.007
Haemoglobin 1.69 (1.16, 2.46) 0.007
Knee involvement (count) 0.86 (0.49, 1.49) 0.59
Wrist involvement (count) 0.76 (0.43, 1.33) 0.33
Cervical spine involvement 11 (3.7) 0.38 (0.07, 2.21) 0.28
JADAS-71 0.99 (0.93, 1.06) 0.76
Therapy during follow-up
None 50 (16.8) Reference category
IACI ± NSAIDs 56 (18.8) 3.03 (0.99, 9.26) 0.05
MTX ± steroids 151 (50.7) 2.24 (0.79, 6.32) 0.13
Biologic agents 41 (13.8) 6.90 (1.68, 28.41) 0.007
Interval between baseline and visit, y 3.83 (1.75, 8.35) 0.0007
AUC-like statistic
Minimum Mean Maximum
Training data 0.78 0.79 0.81
Test data 0.71 0.72 0.74
Included variables showed a univariate P<0.1 and no bivariate correlations (Spearman’s jrj4 0.6). AUC:
area under the curve; IACI: intra-articular corticosteroid injections; JADAS: juvenile arthritis DAS; m: number
of visits; n: number of patients.
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patients). Many predictors in the multivariable analysis
were not significant. This, coupled with the fact that the
number of patients in the subgroups was substantially
lower with respect to the full cohort, might indicate that
the increased predictive performance was due to over-
fitting. Further validation and optimization of the models
is needed.
In conclusion, the prognosis of JIA could not be pre-
dicted accurately in this well-defined cohort of treat-
ment-naı¨ve patients at disease onset, using clinical,
imaging, microbiota and Luminex data and a wide array
of statistical algorithms. The main impediment to an ac-
curate prediction could be the heterogeneity of the dis-
ease and better definition of homogeneous subgroups
may lead to improved predictions. Indeed, prediction
accuracy improved when analysing oligoarticular,
polyarticular RF negative and ANA positive patients sep-
arately. The subgroup models showed that the duration of
morning stiffness was associated with decreased odds of
inactive disease, highlighting the importance of the pa-
tients’ evaluation of disease activity. Moreover,
Mogibacteriaceae were associated with lower odds of in-
active disease in oligoarticular patients and CXCL-9 in
polyarticular patients. Efforts should be directed at validat-
ing the prognostic value of this OTU and chemokine and at
elucidating their potential role in the pathogenesis of JIA.
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